Home Sleep Testing (HST), Industry News, Research/Studies, Technology

Huxley Medical Expands SANSA Diagnostic Platform with Point-of-Care Enrollment and Additional Cardiovascular Risk Marker

Huxley Medical, a commercial-stage medical technology company expanding access to sleep apnea testing across health systems, cardiology, and primary care, today introduced two additions to its SANSA® platform: SANSA GO™, a point-of-care enrollment model that enables clinics to dispense SANSA at patient visits, and hypoxic burden, an additional measure of […]

Home Sleep Testing (HST), Product/Vendor Updates, Research/Studies

Wesper to Unveil First Multi-Tier Sleep Diagnostic Ecosystem for Personalized Sleep Care at SLEEP 2026

Wesper unveiled its multi-tier sleep diagnostic ecosystem at SLEEP 2026, the annual meeting of the Associated Professional Sleep Societies. The ecosystem brings two purpose-built diagnostic pathways, Wesper Lab and Wesper Lite, onto one platform, one patient record, and one interpretation pipeline, so physicians can match the right test to the right […]

Central Disorders of Hypersomnolence, Clinical Insights

Alkermes Presents Alixorexton and LUMRYZ Data at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

Alkermes plc announced plans to present new data from its industry-leading portfolio of sleep medicine research at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026 in Baltimore, MD. The company will present 26 abstracts, including posters featuring LUMRYZ® (sodium oxybate) extended-release oral […]

Idiopathic Hypersomnia, Narcolepsy, Sleep Pharmaceuticals

Jazz Pharmaceuticals to Present Data at SLEEP 2026 Highlighting Effects of Xywav for Narcolepsy and Idiopathic Hypersomnia

Jazz Pharmaceuticals announced that the company will present 21 abstracts, including 11 late-breaking abstracts, at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 14-17, 2026, in Baltimore. The robust breadth of data reflects Jazz’s continued focus on advancing treatment for rare and difficult-to-treat sleep […]